These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

793 related items for PubMed ID: 31117850

  • 1. Blood Eosinophil Counts, Withdrawal of Inhaled Corticosteroids and Risk of COPD Exacerbations and Mortality in the Clinical Practice Research Datalink (CPRD).
    Oshagbemi OA, Franssen FME, van Kraaij S, Braeken DCW, Wouters EFM, Maitland-van der Zee AH, Driessen JHM, de Vries F.
    COPD; 2019 Apr; 16(2):152-159. PubMed ID: 31117850
    [Abstract] [Full Text] [Related]

  • 2. Absolute Blood Eosinophil Counts to Guide Inhaled Corticosteroids Therapy Among Patients with COPD: Systematic Review and Meta-analysis.
    Oshagbemi OA, Odiba JO, Daniel A, Yunusa I.
    Curr Drug Targets; 2019 Apr; 20(16):1670-1679. PubMed ID: 31393244
    [Abstract] [Full Text] [Related]

  • 3. C-reactive protein as a biomarker of response to inhaled corticosteroids among patients with COPD.
    Oshagbemi OA, Franssen FME, Wouters EFM, Maitland-van der Zee AH, Driessen JHM, de Boer A, de Vries F.
    Pulm Pharmacol Ther; 2020 Feb; 60():101870. PubMed ID: 31785343
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Comparative effectiveness of LABA-ICS versus LAMA as initial treatment in COPD targeted by blood eosinophils: a population-based cohort study.
    Suissa S, Dell'Aniello S, Ernst P.
    Lancet Respir Med; 2018 Nov; 6(11):855-862. PubMed ID: 30343028
    [Abstract] [Full Text] [Related]

  • 6. Blood eosinophilia, use of inhaled corticosteroids, and risk of COPD exacerbations and mortality.
    Oshagbemi OA, Franssen FME, Braeken DCW, Henskens Y, Wouters EFM, Maitland-van der Zee AH, Burden AM, de Vries F.
    Pharmacoepidemiol Drug Saf; 2018 Nov; 27(11):1191-1199. PubMed ID: 30264901
    [Abstract] [Full Text] [Related]

  • 7. Withdrawal of inhaled corticosteroids versus continuation of triple therapy in patients with COPD in real life: observational comparative effectiveness study.
    Magnussen H, Lucas S, Lapperre T, Quint JK, Dandurand RJ, Roche N, Papi A, Price D, Miravitlles M, Respiratory Effectiveness Group (REG).
    Respir Res; 2021 Jan 21; 22(1):25. PubMed ID: 33478491
    [Abstract] [Full Text] [Related]

  • 8. Clinical burden of illness among patients with severe eosinophilic COPD.
    Müllerová H, Meeraus WH, Galkin DV, Albers FC, Landis SH.
    Int J Chron Obstruct Pulmon Dis; 2019 Jan 21; 14():741-755. PubMed ID: 31114180
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Blood eosinophil count and pneumonia risk in patients with chronic obstructive pulmonary disease: a patient-level meta-analysis.
    Pavord ID, Lettis S, Anzueto A, Barnes N.
    Lancet Respir Med; 2016 Sep 21; 4(9):731-741. PubMed ID: 27460163
    [Abstract] [Full Text] [Related]

  • 13. Effects of inhaled corticosteroids /long-acting agonists in a single inhaler versus inhaled corticosteroids alone on all-cause mortality, pneumonia, and fracture in chronic obstructive pulmonary disease: A nationwide cohort study 2002-2013.
    Cho KH, Kim YS, Linton JA, Nam CM, Choi Y, Park EC.
    Respir Med; 2017 Sep 21; 130():75-84. PubMed ID: 29206637
    [Abstract] [Full Text] [Related]

  • 14. Effectiveness using higher inhaled corticosteroid dosage in patients with COPD by different blood eosinophilic counts.
    Cheng SL, Lin CH.
    Int J Chron Obstruct Pulmon Dis; 2016 Sep 21; 11():2341-2348. PubMed ID: 27703344
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. COPD patients prescribed inhaled corticosteroid in primary care: time for re-assessment based on exacerbation rate and blood eosinophils?
    Savran O, Godtfredsen N, Sørensen T, Jensen C, Ulrik CS.
    Respir Res; 2021 Feb 12; 22(1):54. PubMed ID: 33579297
    [Abstract] [Full Text] [Related]

  • 18. Demographic and Clinical Characteristics of COPD Patients at Different Blood Eosinophil Levels in the UK Clinical Practice Research Datalink.
    Landis S, Suruki R, Maskell J, Bonar K, Hilton E, Compton C.
    COPD; 2018 Apr 12; 15(2):177-184. PubMed ID: 29558236
    [Abstract] [Full Text] [Related]

  • 19. Blood eosinophils and inhaled corticosteroids in patients with COPD: systematic review and meta-analysis.
    Cheng SL.
    Int J Chron Obstruct Pulmon Dis; 2018 Apr 12; 13():2775-2784. PubMed ID: 30233168
    [Abstract] [Full Text] [Related]

  • 20. Inhaled corticosteroids, blood eosinophils, and FEV1 decline in patients with COPD in a large UK primary health care setting.
    Whittaker HR, Müllerova H, Jarvis D, Barnes NC, Jones PW, Compton CH, Kiddle SJ, Quint JK.
    Int J Chron Obstruct Pulmon Dis; 2019 Apr 12; 14():1063-1073. PubMed ID: 31213788
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 40.